Tags

Type your tag names separated by a space and hit enter

Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
Clin Exp Gastroenterol. 2009; 2:117-28.CE

Abstract

Although proton pump inhibitors (PPI) have a record of remarkable effectiveness and safety in the management of gastroesophageal reflux disease (GERD), several treatment challenges with PPI have emerged. Dexlansoprazole MR is the (R)-enantiomer of lansoprazole contained in a formulation that produces two distinct releases of drug and significantly extends the duration of active plasma concentrations and % time pH > 4 beyond that of conventional single-release PPI. Dexlansoprazole MR can be administered without regard to meals or the timing of meals in most patients. Dexlansoprazole MR 60 mg demonstrated similar efficacy for healing of erosive esophagitis at 8 weeks compared with lansoprazole 30 mg, and dexlansoprazole MR 30 mg was superior to placebo for maintenance of healed erosive esophagitis at 6 months with 99% of nights and 96% of days heartburn-free over 6 months in patients taking dexlansoprazole MR 30 mg. Superior relief of heartburn occurred in patients taking dexlansoprazole MR 30 mg (55% heartburn-free 24-hour periods) vs placebo (14%) for symptomatic nonerosive GERD. The safety profile of dexlansoprazole MR is similar to that of lansoprazole. The extended pharmacodynamic effects, added convenience, and efficacy and safety of dexlansoprazole MR offer a novel approach to gastric pH control in patients with acid-related disorders.

Authors+Show Affiliations

Takeda Pharmaceuticals North America, Inc.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21694835

Citation

Wittbrodt, Eric T., et al. "Delayed Release Dexlansoprazole in the Treatment of GERD and Erosive Esophagitis." Clinical and Experimental Gastroenterology, vol. 2, 2009, pp. 117-28.
Wittbrodt ET, Baum C, Peura DA. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis. Clin Exp Gastroenterol. 2009;2:117-28.
Wittbrodt, E. T., Baum, C., & Peura, D. A. (2009). Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis. Clinical and Experimental Gastroenterology, 2, 117-28.
Wittbrodt ET, Baum C, Peura DA. Delayed Release Dexlansoprazole in the Treatment of GERD and Erosive Esophagitis. Clin Exp Gastroenterol. 2009;2:117-28. PubMed PMID: 21694835.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis. AU - Wittbrodt,Eric T, AU - Baum,Charles, AU - Peura,David A, Y1 - 2009/11/17/ PY - 2009/11/16/received PY - 2011/6/23/entrez PY - 2009/1/1/pubmed PY - 2009/1/1/medline KW - GERD KW - TAK-390MR KW - dexlansoprazole MR KW - erosive esophagitis KW - gastroesophageal reflux disease SP - 117 EP - 28 JF - Clinical and experimental gastroenterology JO - Clin Exp Gastroenterol VL - 2 N2 - Although proton pump inhibitors (PPI) have a record of remarkable effectiveness and safety in the management of gastroesophageal reflux disease (GERD), several treatment challenges with PPI have emerged. Dexlansoprazole MR is the (R)-enantiomer of lansoprazole contained in a formulation that produces two distinct releases of drug and significantly extends the duration of active plasma concentrations and % time pH > 4 beyond that of conventional single-release PPI. Dexlansoprazole MR can be administered without regard to meals or the timing of meals in most patients. Dexlansoprazole MR 60 mg demonstrated similar efficacy for healing of erosive esophagitis at 8 weeks compared with lansoprazole 30 mg, and dexlansoprazole MR 30 mg was superior to placebo for maintenance of healed erosive esophagitis at 6 months with 99% of nights and 96% of days heartburn-free over 6 months in patients taking dexlansoprazole MR 30 mg. Superior relief of heartburn occurred in patients taking dexlansoprazole MR 30 mg (55% heartburn-free 24-hour periods) vs placebo (14%) for symptomatic nonerosive GERD. The safety profile of dexlansoprazole MR is similar to that of lansoprazole. The extended pharmacodynamic effects, added convenience, and efficacy and safety of dexlansoprazole MR offer a novel approach to gastric pH control in patients with acid-related disorders. SN - 1178-7023 UR - https://www.unboundmedicine.com/medline/citation/21694835/Delayed_release_dexlansoprazole_in_the_treatment_of_GERD_and_erosive_esophagitis_ L2 - https://dx.doi.org/10.2147/ceg.s5765 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.